ERBB2 and neoplasm: The coupling results in a high DAR of 7.7, enabling anti-tumor effects even in HER2 low-expressing models not being feasible with ADCs exhibiting lower DAR (including T-DM1/ado-Trastuzumab Emtansine) (161, 162).